Press Room

DCAT Week 2026

Start
Monday, March 23, 2026
End
Thursday, March 26, 2026
Location: New York, United States

Hovione is excited to be once again attending the DCAT Week, the premier global event held annually in New York City for companies engaged in the Bio/Pharmaceutical Manufacturing Value Chain.

Meet the Hovione team. This is the perfect opportunity to speak with our experts and learn how we are supporting our customers worldwide in developing novel drugs that make a difference for patients. Get to know more about:

  • Our One-Site Solution
    Hovione can deliver your entire project from one site, giving you the benefit of compressed timelines, seamless project management and knowledge, and increased sustainability.
     
  • Our Leadership in Spray Drying
    With the largest number of commercial projects, the best science and engineering, the largest capacity, and the most experienced team, Hovione can take your project from development to market like no one else.
     
  • Our Continuous Tableting Expertise
    For those aiming to go from development to manufacturing in record time with high quality and less variability, Hovione is Bridging Science and Manufacturing, allowing your drug product to be made faster and more efficiently today! Hovione can support Continuous Tableting based programs, including new products as well as batch to continuous conversions.
     
  • Our Innovative Platforms
    At Hovione we have a reputation for transforming nascent technologies into large-scale GMP-compliant platforms by building strategic partnerships with our customers and technology partners. We look forward to seeing you to share some exciting news.

 

Schedule a meeting today.

schedule a meeting

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025